Biotest Aktiengesellschaft (BIO.DE)
EUR 41.4
(0.49%)
EUR 41.4
(0.49%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 377.3 Million EUR | -33.21% |
| 2022 | 564.9 Million EUR | 15.31% |
| 2021 | 489.9 Million EUR | 6.22% |
| 2020 | 461.2 Million EUR | 14.64% |
| 2019 | 402.3 Million EUR | 22.39% |
| 2018 | 328.7 Million EUR | 14.61% |
| 2017 | 286.8 Million EUR | -13.09% |
| 2016 | 330 Million EUR | -1.64% |
| 2015 | 335.5 Million EUR | 2.98% |
| 2014 | 325.8 Million EUR | 44.03% |
| 2013 | 226.2 Million EUR | 218.44% |
| 2012 | 71.03 Million EUR | -54.34% |
| 2011 | 155.58 Million EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| 2003 | - EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 429.5 Million EUR | 13.84% |
| 2024 Q2 | 429.7 Million EUR | -13.34% |
| 2023 Q2 | 628.5 Million EUR | 1.55% |
| 2023 FY | 377.3 Million EUR | -33.21% |
| 2023 Q4 | 377.3 Million EUR | -42.13% |
| 2023 Q3 | 652 Million EUR | 3.74% |
| 2023 Q1 | 618.9 Million EUR | 9.56% |
| 2022 Q1 | 498.1 Million EUR | 1.67% |
| 2022 FY | 564.9 Million EUR | 15.31% |
| 2022 Q4 | 564.9 Million EUR | 12.04% |
| 2022 Q3 | 504.2 Million EUR | 0.82% |
| 2022 Q2 | 500.1 Million EUR | 0.4% |
| 2021 Q3 | 496.3 Million EUR | 1.37% |
| 2021 Q2 | 489.6 Million EUR | 5.59% |
| 2021 Q1 | 463.7 Million EUR | 0.54% |
| 2021 Q4 | 489.9 Million EUR | -1.29% |
| 2021 FY | 489.9 Million EUR | 6.22% |
| 2020 Q3 | 460.6 Million EUR | 0.3% |
| 2020 FY | 461.2 Million EUR | 14.64% |
| 2020 Q1 | 405.9 Million EUR | 0.89% |
| 2020 Q4 | 461.2 Million EUR | 0.13% |
| 2020 Q2 | 459.2 Million EUR | 13.13% |
| 2019 Q4 | 402.3 Million EUR | -0.37% |
| 2019 Q2 | 52.3 Million EUR | -85.07% |
| 2019 Q3 | 403.8 Million EUR | 672.08% |
| 2019 FY | 402.3 Million EUR | 22.39% |
| 2019 Q1 | 350.3 Million EUR | 6.57% |
| 2018 FY | 328.7 Million EUR | 14.61% |
| 2018 Q4 | 328.7 Million EUR | 3.11% |
| 2018 Q3 | 318.8 Million EUR | -11.62% |
| 2018 Q2 | 360.7 Million EUR | 79.1% |
| 2018 Q1 | 201.4 Million EUR | -29.78% |
| 2017 FY | 286.8 Million EUR | -13.09% |
| 2017 Q4 | 286.8 Million EUR | -26.18% |
| 2017 Q3 | 388.5 Million EUR | -1.99% |
| 2017 Q2 | 396.4 Million EUR | 18.93% |
| 2017 Q1 | 333.3 Million EUR | 1.0% |
| 2016 Q1 | 339.5 Million EUR | 1.19% |
| 2016 FY | 330 Million EUR | -1.64% |
| 2016 Q4 | 330 Million EUR | -0.18% |
| 2016 Q3 | 330.6 Million EUR | -1.2% |
| 2016 Q2 | 334.6 Million EUR | -1.44% |
| 2015 Q4 | 335.5 Million EUR | -0.27% |
| 2015 FY | 335.5 Million EUR | 2.98% |
| 2015 Q1 | 336.7 Million EUR | 3.35% |
| 2015 Q2 | 338.3 Million EUR | 0.48% |
| 2015 Q3 | 336.4 Million EUR | -0.56% |
| 2014 Q2 | 241.1 Million EUR | 0.17% |
| 2014 FY | 325.8 Million EUR | 44.03% |
| 2014 Q4 | 325.8 Million EUR | 34.74% |
| 2014 Q3 | 241.8 Million EUR | 0.29% |
| 2014 Q1 | 240.7 Million EUR | 6.41% |
| 2013 Q2 | 70.1 Million EUR | 11.98% |
| 2013 Q3 | 68.2 Million EUR | -2.71% |
| 2013 Q4 | 226.2 Million EUR | 231.67% |
| 2013 FY | 226.2 Million EUR | 218.44% |
| 2013 Q1 | 62.6 Million EUR | -11.87% |
| 2012 Q3 | 152.1 Million EUR | -2.56% |
| 2012 Q4 | 71.03 Million EUR | -53.3% |
| 2012 FY | 71.03 Million EUR | -54.34% |
| 2012 Q1 | 152.5 Million EUR | -1.98% |
| 2012 Q2 | 156.1 Million EUR | 2.36% |
| 2011 Q2 | 178.2 Million EUR | 0.0% |
| 2011 FY | 155.58 Million EUR | 0.0% |
| 2011 Q3 | 182.4 Million EUR | 2.36% |
| 2011 Q4 | 155.58 Million EUR | -14.7% |
| 2011 Q1 | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q3 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 Q1 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| 2003 FY | - EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioNTech SE | 191 Million EUR | -97.539% |
| CureVac N.V. | 36.81 Million EUR | -924.743% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 0.0% |
| BRAIN Biotech AG | 25.19 Million EUR | -1397.638% |
| Formycon AG | 7.81 Million EUR | -4727.895% |
| Heidelberg Pharma AG | 70.4 Thousand EUR | -535784.216% |
| Medigene AG | 2.03 Million EUR | -18431.434% |